Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Intract Pharma Limited currently manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners, indicating a broader prosecution front than a single-application portfolio. This spread suggests that the company is pursuing multiple distinct innovations or different aspects of a pharmaceutical platform simultaneously. Practitioners can expect to manage multiple examiner timelines and varying sets of technical objections within this sector.
Sudhakar Katakam is the busiest examiner for the company, with 1 busiest examiner pending action. The portfolio's activity is spread across 2 distinct art units. Because the 2 pending office actions are split between different examiners and art units, the company is engaging with multiple points of review within the biotechnology sector. This indicates that the company's current intellectual property strategy is not limited to a single technical niche. The involvement of 2 distinct art units suggests that the underlying technology may have applications across different pharmaceutical classifications, requiring a coordinated approach to maintain consistency across the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KATAKAM, SUDHAKAR | 1 | 74.8% | +23.3% |
| GREENE, IVAN A | 1 | 18.8% | +6.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17611899 | COMPOSITIONS OF PROTEINS WITH DIPEPTIDES AS STABILISING AGENTS | GREENE, IVAN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18252438 | PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE AS ACTIVE INGREDIENT | KATAKAM, SUDHAKAR | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18252438 | PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE AS ACTIVE INGREDIENT | KATAKAM, SUDHAKAR | 1658 | §103 | Non-Final OA | — | Pending | May 10, 2023 |
| 17611899 | COMPOSITIONS OF PROTEINS WITH DIPEPTIDES AS STABILISING AGENTS | GREENE, IVAN A | 1619 | §103§112 | Non-Final OA | — | Pending | Nov 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIntract Pharma Limited has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Sudhakar Katakam has the most, with 1 of Intract Pharma Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
